ICPO Forum 2025: advancing theranostics in precision oncology
- PMID: 40599741
- PMCID: PMC12212103
- DOI: 10.1016/j.lanepe.2025.101357
ICPO Forum 2025: advancing theranostics in precision oncology
Conflict of interest statement
Richard Paul Baum is an advisor to 3B Pharmaceuticals, ITM, Novartis, Swiss Rockets, and Telix Pharmaceuticals. He is founder/co-founder of RadioVaxx, NucleoGenesis, and ZENTA. He is member of the ICPO Board of Trustees, and President of the ICPO Academy (no payment). Odile Jaume has no competing interest to declare.
References
-
- Pomykala K.L., Hadaschik B.A., Sartor O., et al. Next generation radiotheranostics promoting precision medicine. Ann Oncol. 2023;34(6):507–519. https://www.annalsofoncology.org/article/S0923-7534(23)00113-8/fulltext - PubMed
-
- Abdel-Wahab M., Giammarile F., Carrara M., et al. Radiotherapy and theranostics: a lancet oncology commission. Lancet Oncol. 2024;25:e545–e580. www.thelancet.com/commissions-do/radiotherapy-theranostics - PubMed
-
- Benefits & expectations of an ICPO accredited theranostics center. www.icpo.foundation/icpo-centers/benefits-expectations/
-
- ICPO Academy for theranostics. www.theranostics.academy
LinkOut - more resources
Full Text Sources
